The Impact of Systemic Therapy Following Ductal Carcinoma In Situ
The Impact of Systemic Therapy Following Ductal Carcinoma In Situ
复制标题
DOI：
10.1093/jncimonographs/lgq021
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Swain, Sandra M.
中科院分区：
文献类型：
--
作者：
Eng-Wong, Jennifer;Costantino, Joseph P.;Swain, Sandra M.
在导管原位癌(DCIS)的局部治疗后，他莫昔芬可将同侧和对侧乳腺癌的风险降低30%-50%。他莫昔芬在切除DCIS的女性中的研究没有显示出对总体或癌症特异性生存的任何影响。他莫昔芬的不良事件特征描述良好，应评估个体风险和收益以指导决策。我们回顾了他莫昔芬在DCIS中的第三阶段试验结果以及新出现的降低风险的疗法。
Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.